BiotechTube
Agios Pharmaceuticals

Agios Pharmaceuticals

AGIO
Cambridge, United States· Est. 2008

Founded in 2008, Agios Pharmaceuticals is a leader in the science of cellular metabolism, initially making its mark with the discovery of IDH inhibitors leading to two approved cancer drugs. The company has since strategically pivoted to focus exclusively on rare diseases, particularly hemolytic anemias, leveraging its pioneering PK activation platform. With one approved rare disease therapy and a robust late-stage pipeline, Agios is positioned to address significant unmet needs in thalassemia and sickle cell disease, supported by a strong corporate culture centered on patient connections.

agios.com

AGIO · Stock Price

USD 28.352.05 (-6.74%)
Market Cap: $1.7B

Historical price data

AI Company Overview

Founded in 2008, Agios Pharmaceuticals is a leader in the science of cellular metabolism, initially making its mark with the discovery of IDH inhibitors leading to two approved cancer drugs. The company has since strategically pivoted to focus exclusively on rare diseases, particularly hemolytic anemias, leveraging its pioneering PK activation platform. With one approved rare disease therapy and a robust late-stage pipeline, Agios is positioned to address significant unmet needs in thalassemia and sickle cell disease, supported by a strong corporate culture centered on patient connections.

Rare DiseasesHematologyHemolytic Anemias

Technology Platform

A pioneering platform in cellular metabolism, with a current focus on pyruvate kinase (PK) activation to improve red blood cell health and treat the root cause of hemolytic anemias.

Pipeline

49
49 drugs in pipeline8 in Phase 3
DrugIndicationStageWatch
MitapivatPyruvate Kinase DeficiencyApproved
Mitapivat + Mitapivat-matching placeboPediatric Pyruvate Kinase DeficiencyPhase 3
Mitapivat + Mitapivat-matching placeboPediatric Pyruvate Kinase DeficiencyPhase 3
Placebo Matching Mitapivat + MitapivatTransfusion-dependent Alpha-ThalassemiaPhase 3
MitapivatPyruvate Kinase DeficiencyPhase 3

Funding History

4
Total raised:$417M
PIPE$200MJun 15, 2016
IPO$106MJul 24, 2013
Series B$78MApr 15, 2010
Series A$33MJan 15, 2008

FDA Approved Drugs

2
PYRUKYNDNDAFeb 17, 2022
AQVESMENDAFeb 17, 2022

Opportunities

Agios has significant growth opportunities in expanding mitapivat's label into larger rare disease markets like thalassemia and sickle cell disease, where positive Phase 3 data could drive blockbuster potential.
The development of its next-generation PK activator, AG-946, offers a pipeline-in-a-product opportunity for improved efficacy or new indications.
Furthermore, the company's productive research engine could yield new preclinical candidates to sustain long-term growth.

Risk Factors

Key risks include clinical trial failures for mitapivat in thalassemia or sickle cell disease, which are essential for future growth.
The company faces commercialization challenges in launching a therapy for an ultra-rare disease (PK deficiency) and intense future competition in broader anemia markets.
Agios also has financial execution risk, as it currently operates at a loss and must carefully manage its cash runway to fund expensive late-stage trials.

Competitive Landscape

In PK deficiency, Agios's Pyrukynd is the first and only approved therapy, giving it a monopoly. In thalassemia and sickle cell disease, it will compete with established drugs like luspatercept, crizanlizumab, and voxelotor, as well as emerging gene therapies. Agios's differentiation lies in its oral, small-molecule approach targeting cellular metabolism, which offers potential advantages in convenience and cost over biologics and complex gene therapies.